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Background
Generating highly functional antibodies against HIV-1 is
critical to prevent infection. Here we evaluated the ability
of CD40L (a co-stimulatory molecule for B cells and den-
dritic cells) as an adjuvant to prevent mucosal infection
from neutralization-susceptible (SIVE660) and neutraliza-
tion-resistant (SIV251) SIVs.
Methods
Groups of rhesus macaques (10-15 animals/group) were
immunized intramuscularly at 0 and 8 weeks with 3mg of
DNA/SIV or DNA/SIV-CD40L, and boosted with 108 pfu
of MVA/SIV at 16 and 24 weeks. In addition, animals
challenged with SIV251 received 106 pfu of MVA/CD40L
premixed with MVA/SIV immunizations. Both the DNA
and MVA immunogens expressed SIV239 Gag, Pol and
Env. At about 24 weeks after final vaccination, animals
were challenged intrarectally with either SIV251 (8 weekly
doses) or SIVE660 (12 weekly doses) until all unvaccinated
controls became infected.
Results
Adjuvanting DNA with CD40L enhanced (p<0.05) the
titer and avidity of antibodies against SIV239 and
SIVE660 Envs. Adjuvanting both DNA and MVA with
CD40L enhanced (p<0.05) the frequency of B cell follicles
with germinal centers (sites of antibody affinity matura-
tion) in the lymph nodes. Following challenge, animals
vaccinated with CD40L adjuvant showed markedly
enhanced protection from virus acquisition against both
SIVE660 (number of challenges for 50% infection was 2
in controls, 5 in DNA/MVA and 12 in DNA/MVA with
CD40L; p=0.003, 76% vaccine efficacy) and SIV251
(number of challenges for 50% infection was 2 in con-
trols, 2 in DNA/MVA and 6 in DNA/MVA with CD40L;
p=0.04, 55% vaccine efficacy). The enhanced protection
against SIVE660 correlated directly with increased avidity
of anti-SIVE660 Env antibody and correlation analyses
for protection against SIV251 are ongoing. CD40L-adju-
vanted animals also showed 100-fold reduction in peak
virus replication in both infection models.
Conclusion
These results demonstrate that CD40L enhances the
functional quality of anti-Env antibody and protection
from acquisition of neutralization sensitive and resistant
mucosal SIV infections.
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